Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 209,973,664 papers from all fields of science
Search
Sign In
Create Free Account
atorvastatin
Known as:
(betaR,deltaR)-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic Acid
, (betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-pyrrole-1-heptanoic Acid
A synthetic lipid-lowering agent. Atorvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
36 relations
Amlodipine / atorvastatin
Amlodipine 5 MG / atorvastatin 80 MG Oral Tablet [Caduet]
Atorvastatin Sodium
Atorvastatin calcium
Expand
Broader (2)
Anticholesteremic Agents
Pyrroles
Narrower (6)
CI 981
Caduet
Lipitor
Liptruzet
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2006
Highly Cited
2006
High-dose atorvastatin after stroke or transient ischemic attack.
P. Amarenco
,
J. Bogousslavsky
,
+8 authors
J. Zivin
New England Journal of Medicine
2006
Corpus ID: 43012735
BACKGROUND Statins reduce the incidence of strokes among patients at increased risk for cardiovascular disease; whether they…
Expand
Highly Cited
2006
Highly Cited
2006
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute.
Sidney C. Smith
,
Jerilyn K Allen
,
+11 authors
K. Taubert
Journal of the American College of Cardiology
2006
Corpus ID: 38293285
Highly Cited
2005
Highly Cited
2005
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
T. Pedersen
,
O. Faergeman
,
+8 authors
J. Tsai
JAMA
2005
Corpus ID: 20394477
CONTEXT Evidence suggests that more intensive lowering of low-density lipoprotein cholesterol (LDL-C) than is commonly applied…
Expand
Highly Cited
2005
Highly Cited
2005
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
J. Larosa
,
S. Grundy
,
+8 authors
N. Wenger
New England Journal of Medicine
2005
Corpus ID: 24817206
Highly Cited
2005
Highly Cited
2005
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
C. Wanner
,
V. Krane
,
+4 authors
E. Ritz
New England Journal of Medicine
2005
Corpus ID: 20919404
Highly Cited
2004
Highly Cited
2004
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
H. Colhoun
,
D. Betteridge
,
+7 authors
J. Fuller
The Lancet
2004
Corpus ID: 28885209
Review
2003
Review
2003
Clinical Pharmacokinetics of Atorvastatin
H. Lennernäs
Clinical Pharmacokinetics
2003
Corpus ID: 44811760
Hypercholesterolaemia is a risk factor for the development of atherosclerotic disease. Atorvastatin lowers plasma low-density…
Expand
Highly Cited
2002
Highly Cited
2002
The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease
S. Youssef
,
O. Stüve
,
+8 authors
S. Zamvil
Nature
2002
Corpus ID: 4301535
Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, which are approved for cholesterol reduction, may…
Expand
Highly Cited
2002
Highly Cited
2002
Cellular Antioxidant Effects of Atorvastatin In Vitro and In Vivo
S. Wassmann
,
U. Laufs
,
+6 authors
G. Nickenig
Arteriosclerosis, Thrombosis and Vascular Biology
2002
Corpus ID: 579958
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) may exert direct effects on vascular cells and beneficially…
Expand
Highly Cited
2001
Highly Cited
2001
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study.
G. Schwartz
,
A. Olsson
,
+7 authors
T. Stern
Indian Heart Journal
2001
Corpus ID: 2898155
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study : A randomized…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE